Nutrients (Nov 2022)

Blackcurrants Reduce the Risk of Postmenopausal Osteoporosis: A Pilot Double-Blind, Randomized, Placebo-Controlled Clinical Trial

  • Briana M. Nosal,
  • Junichi R. Sakaki,
  • Zachary Macdonald,
  • Kyle Mahoney,
  • Kijoon Kim,
  • Matthew Madore,
  • Staci Thornton,
  • Thi Dong Binh Tran,
  • George Weinstock,
  • Elaine Choung-Hee Lee,
  • Ock K. Chun

DOI
https://doi.org/10.3390/nu14234971
Journal volume & issue
Vol. 14, no. 23
p. 4971

Abstract

Read online

Beneficial effects of blackcurrant supplementation on bone metabolism in mice has recently been demonstrated, but no studies are available in humans. The current study aimed to examine the dose-dependent effects of blackcurrant in preventing bone loss and the underlying mechanisms of action in adult women. Forty peri- and early postmenopausal women were randomly assigned into one of three treatment groups for 6 months: (1) a placebo (control group, n = 13); (2) 392 mg/day of blackcurrant powder (low blackcurrant, BC, group, n = 16); and (3) 784 mg/day of blackcurrant powder (high BC group, n = 11). The significance of differences in outcome variables was tested by repeated-measures ANOVA with treatment and time as between- and within-subject factors, respectively. Overall, blackcurrant supplementation decreased the loss of whole-body bone mineral density (BMD) compared to the control group (p p p < 0.05). These findings suggest that daily consumption of 784 mg of blackcurrant powder for six months mitigates the risk of postmenopausal bone loss, potentially through enhancing bone formation. Further studies of larger samples with various skeletal conditions are warranted to confirm these findings.

Keywords